As growing technical advances are made in immunotherapy for treating cancers, the concern for anti-PD-(L)1 therapy grows and an increasing number of studies evaluating the cost-effectiveness of anti-PD-(L)1 agents have emerged in recent 3 years. This evidence concerns the gene CD274 and cancer.